Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications

Lazreg, Sihem; Merad, Z.; Nouri, Milad; Garout, R.; Derdour, A; Ghroud, N; Kherroubi, R.; Meziane, M.; Belkacem, Sabrina; Ouhadj, O.; Baudouin, Christophe; Tiar, M.

doi:10.1016/j.jfo.2018.04.012

Cited by 19 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from timolol 0.5% solution, Quaranta et al reported Timogel 0.1% (timolol 0.1% in gel-forming carbomers) to demonstrate a comparable efficacy with solution preparation to decrease mean 24-hour IOP, diurnal, nocturnal, and individual time point IOP [99]. The use of timolol in a carbomer gel form is able to achieve a similar control in the IOP profile, but in a lower concentration which reduces dry eye-like symptoms and make the medication better tolerated [100, 101]. Dorzolamide, when dosed three times daily, has been shown to lower circadian IOP by 15–23% [83, 85, 90, 102].…”

Section: Therapeutic Efficacy Of Current Glaucoma Management Modalmentioning

confidence: 99%

Role of 24-Hour Intraocular Pressure Monitoring in Glaucoma Management

Wong

2019

Journal of Ophthalmology

View full text Add to dashboard Cite

Glaucoma is the leading cause of irreversible blindness worldwide and the prevalence is on the rising trend. Intraocular pressure (IOP) reduction is the mainstay of treatment. The current practice of IOP monitoring is based on spot measurements during clinic visits during office hours. However, there are up to 50% of glaucoma patients who had normal initial IOP, while some treated patients continued to have progressive glaucomatous optic nerve damage even with a low IOP. Recent studies have shown that the IOP of glaucoma patients fluctuated during the day with different patterns, and some of them had peak IOP outside office hours. These findings provided us with new insights on the role of 24-hour IOP monitoring in managing normal tension glaucoma and patients with progressive deterioration despite apparently well-controlled IOP. Nevertheless, results to date are rather inconsistent, and there is no consensus yet. In this review, we briefly highlighted the current modalities of 24-hour IOP monitoring and summarized the characteristic 24-hour IOP pattern and the clinical relevance of IOP parameters in predicting glaucomatous progression in different glaucoma subtypes. We also discussed the therapeutic efficacy of current glaucoma treatment modalities with respect to the mentioned 24-hour IOP profiles, so as to strengthen the role of 24-hour IOP monitoring in identifying and stratifying the risks of progression in glaucoma patients, as well as optimizing treatments according to their IOP profiles.

show abstract

Section: Therapeutic Efficacy Of Current Glaucoma Management Modalmentioning

confidence: 99%

Role of 24-Hour Intraocular Pressure Monitoring in Glaucoma Management

Wong

2019

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The mechanism of action of timolol is through reduction in formation of the aqueous humor in the ciliary body in the eye. It was the first beta-blocker approved for topical use in the treatment of glaucoma in the US (1978) ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma

Wang

Liao

Nie

2020

Clinics

View full text Add to dashboard Cite

“…The IOP-lowering outcome of PF timolol 0.1% gel in treatment-naive patients with primary OAG or OHT was effective. Furthermore, this treatment reduced ocular signs and symptoms in patients who were intolerant to preserved eye drops [39]. The IOP-lowering effect of both PF and preserved brimonidine tartrate in patients with OAG or OHT was comparable.…”

Section: Resultsmentioning

confidence: 82%

Pharmaceutical treatment of primary open angle glaucoma

Al-Namaeh¹

2021

Med Hypothesis Discov Innov Optom

View full text Add to dashboard Cite

Background: Glaucoma is a progressive, irreversible optic neuropathy that results in serious vision loss and blindness. This review aimed to summarize key concepts of primary open angle glaucoma (POAG) pharmaceutical treatment trials over the last decade. Methods: We searched PubMed/MEDLINE and clinicaltrials.gov from January 1, 2010, to August 31, 2020, using the key words “POAG” and “Ocular topical therapeutics”. This search yielded 77 and 120 papers, respectively. Results: Thirty-three records were compatible with our inclusion criteria. Pharmaceutical treatment is a common intervention in POAG for lowering IOP. Prostaglandin (PG) analogues are most commonly recommended as initial medical therapy, which are administrated either as a monotherapy or in combination with other IOP-lowering classes of medications. Alternative therapies, such as ?-blockers, ?-2 adrenergic receptor agonists, and topical carbonic anhydrase inhibitors, have been used in combination or as a monotherapy. Rho-kinase inhibitors, such as netarsudil 0.02%, AR-13324 0.02%, and ripasudil are new IOP-lowering medications. Despite IOP reduction, there is a significant number of patients with POAG that may experience disease progression, and the risk of blindness over the long term is considerable. Conclusions: Clinical trials have indicated that pharmaceutical treatment of POAG is effective and safe. In addition, the new novel Rho-kinase inhibitors have shown significant IOP reduction. The new fixed combinations have also yielded significant reductions in IOP. POAG is a cause of irreversible vision loss, if not diagnosed and treated early. The condition is likely to progress in a significant number of patients, with a considerable risk of blindness in the long-term. How to cite this article: Al-Namaeh M. Pharmaceutical treatment of primary open angle glaucoma. Med Hypothesis Discov Innov Optom. 2021 Spring; 2(1): 8-17. DOI: https://doi.org/10.51329/mehdioptometry120

show abstract

Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications

Cited by 19 publications

References 31 publications

Role of 24-Hour Intraocular Pressure Monitoring in Glaucoma Management

Role of 24-Hour Intraocular Pressure Monitoring in Glaucoma Management

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma

Pharmaceutical treatment of primary open angle glaucoma

Contact Info

Product

Resources

About